Single-cell RNA sequencing (scRNA-seq) approaches can be used to understand sample heterogeneity and potential biomarker targets for cancerous tumor samples. However, the logistics of scRNAseq experiments can be challenging to optimize.
For human samples that are not collected in lab settings, fixation or freezing techniques are required to stabilize samples until sent to a centralized lab for processing. Through these methods, cells can be damaged, biological can be information lost, and data quality can be compromised — a cause for heightened concern when working with precious samples.
This application note from Revvity presents results from a Honeycomb beta tester laboratory demonstrating the efficacy of the Hive scRNAseq Solution with a glioblastoma sample. Freshly dissociated cells were captured in a Hive device at the core facility. To accommodate the sample acquisition and preparation lead times, cell-loaded Hive devices were stored after capture and the remainder of the workflow was completed one week later for convenience, without data compromise. The data show a strong recovery of malignant cell types, including astro-mesenchymal and oligodendrocyte precursor cells.
Offered Free by: Revvity Health Sciences
See All Resources from: Revvity Health Sciences